# Trump Administration Aims to Fast-Track Psychedelic Therapies for PTSD
The Trump administration announced plans to accelerate approval of psychedelic-assisted treatments for post-traumatic stress disorder. The initiative targets psilocybin and MDMA therapies currently undergoing FDA review.
The FDA granted breakthrough therapy designation to MDMA-assisted therapy for PTSD in 2017, allowing expedited evaluation. Phase 3 clinical trials showed MDMA combined with psychotherapy produced remission in 71% of PTSD patients, compared to 32% receiving psychotherapy alone. Psilocybin therapy demonstrates similar promise in early research.
The administration's push aims to address a treatment gap for the estimated 3.6% of American adults with PTSD. Current first-line treatments like SSRIs and cognitive behavioral therapy fail for roughly 30% of patients.
However, this accelerated timeline raises questions. These therapies require controlled clinical settings with trained facilitators, not standard office visits. Safety monitoring remains essential since psychedelics carry risks including increased blood pressure and psychological distress during treatment.
The approach differs from traditional approval pathways. Fast-tracking relies on existing evidence rather than generating new data, which could streamline access if therapies prove effective in real-world settings.
Veterans' groups have advocated for this policy, citing treatment-resistant PTSD prevalence in military populations.